Kuendgen A - Search Results

1

Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.

Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N. Kuendgen A, et al. Blood. 2004 Sep 1;104(5):1266-9. doi: 10.1182/blood-2003-12-4333. Epub 2004 May 20. Blood. 2004. PMID: 15155466 Free article. Clinical Trial.

2

Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.

Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, Germing U, Haas R, Gattermann N. Kuendgen A, et al. Ann Hematol. 2005 Dec;84 Suppl 1:61-6. doi: 10.1007/s00277-005-0026-8. Ann Hematol. 2005. PMID: 16270213 Clinical Trial.

3

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.

Kuendgen A, Schmid M, Schlenk R, Knipp S, Hildebrandt B, Steidl C, Germing U, Haas R, Dohner H, Gattermann N. Kuendgen A, et al. Cancer. 2006 Jan 1;106(1):112-9. doi: 10.1002/cncr.21552. Cancer. 2006. PMID: 16323176 Free article. Clinical Trial.

4

Myelodysplastic syndromes in patients younger than age 50.

Kuendgen A, Strupp C, Aivado M, Hildebrandt B, Haas R, Gattermann N, Germing U. Kuendgen A, et al. J Clin Oncol. 2006 Dec 1;24(34):5358-65. doi: 10.1200/JCO.2006.07.5598. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088566

5

Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.

Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R. Germing U, et al. Among authors: kuendgen a. Haematologica. 2006 Dec;91(12):1596-604. Haematologica. 2006. PMID: 17145595

6

Valproic acid for the treatment of myeloid malignancies.

Kuendgen A, Gattermann N. Kuendgen A, et al. Cancer. 2007 Sep 1;110(5):943-54. doi: 10.1002/cncr.22891. Cancer. 2007. PMID: 17647267 Free article. Review.

7

Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.

Balleisen S, Kuendgen A, Hildebrandt B, Haas R, Germing U. Balleisen S, et al. Among authors: kuendgen a. Leuk Res. 2009 Sep;33(9):1189-93. doi: 10.1016/j.leukres.2009.03.004. Epub 2009 May 9. Leuk Res. 2009. PMID: 19428106

8

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes.

Neukirchen J, Blum S, Kuendgen A, Strupp C, Aivado M, Haas R, Aul C, Gattermann N, Germing U. Neukirchen J, et al. Among authors: kuendgen a. Eur J Haematol. 2009 Nov;83(5):477-82. doi: 10.1111/j.1600-0609.2009.01299.x. Epub 2009 Jun 22. Eur J Haematol. 2009. PMID: 19548919 Free article.

9

Change of prognosis of patients with myelodysplastic syndromes during the last 30 years.

Neukirchen J, Nachtkamp K, Schemenau J, Aul C, Giagounidis A, Strupp C, Kuendgen A, Kobbe G, Haas R, Germing U. Neukirchen J, et al. Among authors: kuendgen a. Leuk Res. 2015 Jul;39(7):679-83. doi: 10.1016/j.leukres.2015.04.001. Epub 2015 Apr 15. Leuk Res. 2015. PMID: 25929166

10

Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts.

Maassen A, Strupp C, Giagounidis A, Kuendgen A, Nachtkamp K, Hildebrandt B, Gattermann N, Aul C, Haas R, Germing U. Maassen A, et al. Among authors: kuendgen a. Leuk Res. 2013 Jan;37(1):64-70. doi: 10.1016/j.leukres.2012.09.021. Epub 2012 Oct 31. Leuk Res. 2013. PMID: 23122806

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters